New ChemRxiv preprint! “Pitfalls and considerations in determining the potency and mutant selectivity of covalent #EGFR inhibitors.” Collaboration between our group and AssayQuant Technologies, Inc. #MedicinalChemistry #oncology https://chemrxiv.org/engage/chemrxiv/article-details/64e50861dd1a73847f5020a1

The small molecule SDT-011, tested in mice and human skin, could be a promising treatment for severe #rash associated with the #EGFR inhibitor cancer treatment. @ScienceTM https://scim.ag/33i #press

The small molecule SDT-011, tested in mice and human skin, could be a promising treatment for severe #rash associated with the #EGFR inhibitor cancer treatment. @ScienceTM https://scim.ag/30v #press

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: http://integrityce.com/TBT2023
CME eval🔗: http://integrityce.com/TBTeval23

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: http://integrityce.com/TBT2023
CME eval🔗: http://integrityce.com/TBTeval23

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: http://integrityce.com/TBT2023
CME eval🔗: http://integrityce.com/TBTeval23

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: http://integrityce.com/TBT2023
CME eval🔗: http://integrityce.com/TBTeval23

#TumorBoardTuesday

🔬🧬Tx of #EGFR Exon20 insertion has changed significantly. @LealTiciana @JennyCarlisleMD brought us up to speed at #TumorBoardtuesday

➡️Here’s the Thursday Case 🎀
🆓 #CME: 2 quick❓
ALL CME 🔗: http://integrityce.com/TBT2023
CME eval🔗: http://integrityce.com/TBTeval23

The EGFR #phosphatase RPTPγ is a #redox-regulated suppressor of promigratory signaling
Maitreyi Joshi, Philippe Bastiaens et al show that #RPTPγ is coupled to autocatalytic, ligandless #EGFR #phosphorylation by a ROS-mediated toggle-switch, enabling ultrasensitive EGFR activation at the plasma membrane
https://www.embopress.org/doi/10.15252/embj.2022111806

Online today!
Lung cancer cells exposed to #PM2.5 for 90 days were used as a model of the effects of long-term exposure to PM2.5 on #LungCancer. In mice, tumor progression was enhanced by long-term exposure to PM2.5. The molecular mechanism identified may include (i) activation of #EGFR signaling & (ii) activation of AhR to upregulate TMPRSS2, which in turn upregulates its downstream targets, such as #IL18.

By PC Yang, CY Chen & colleagues, Taiwan

🗞️ https://doi.org/10.15252/emmm.202217014

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 2/6 #TumorBoardTuesday
Thurs Case🎀

#mCRC & #EGFR tx:
✅Anti-EGFR useful in RAS/RAF WT; debate re: timing vs anti-VEGF
✅Pt centered discussion including SEs 🗝️
✅Emerging data: EGFR re-tx, using ctDNA to guide

📚@shafiarahman_ @RischZack’s thread:
https://threadreaderapp.com/thread/1638330517530574851.html

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 4/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 2:

@shafiarahman_ gives us a preview of what might be coming in #EGFR directed tx in #mCRC
🔹Re-challenge based on ctDNA clearance of resistant clones; pts w resistance to EGFRi benefit later as the tumor evolves again
🔹New combos!

RT @JohnEbbenMDPhD
A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge. https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

RT @JohnEbbenMDPhD
A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge. https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge.
---
RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a…
https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 4/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 2:

@shafiarahman_ gives us a preview of what might be coming in #EGFR directed tx in #mCRC
🔹Re-challenge based on ctDNA clearance of resistant clones; pts w resistance to EGFRi benefit later as the tumor evolves again
🔹New combos!

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 2/6 #TumorBoardTuesday
Thurs Case🎀

#mCRC & #EGFR tx:
✅Anti-EGFR useful in RAS/RAF WT; debate re: timing vs anti-VEGF
✅Pt centered discussion including SEs 🗝️
✅Emerging data: EGFR re-tx, using ctDNA to guide

📚@shafiarahman_ @RischZack’s thread:
https://threadreaderapp.com/thread/1638330517530574851.html

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 4/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 2:

@shafiarahman_ gives us a preview of what might be coming in #EGFR directed tx in #mCRC
🔹Re-challenge based on ctDNA clearance of resistant clones; pts w resistance to EGFRi benefit later as the tumor evolves again
🔹New combos!

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 4/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 2:

@shafiarahman_ gives us a preview of what might be coming in #EGFR directed tx in #mCRC
🔹Re-challenge based on ctDNA clearance of resistant clones; pts w resistance to EGFRi benefit later as the tumor evolves again
🔹New combos!

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 2/6 #TumorBoardTuesday
Thurs Case🎀

#mCRC & #EGFR tx:
✅Anti-EGFR useful in RAS/RAF WT; debate re: timing vs anti-VEGF
✅Pt centered discussion including SEs 🗝️
✅Emerging data: EGFR re-tx, using ctDNA to guide

📚@shafiarahman_ @RischZack’s thread:
https://threadreaderapp.com/thread/1638330517530574851.html